Background
OPTIMA has an adaptive design seeking to advance development of personalised medicine in breast cancer by assessing the value of multi-parameter tests, such as Oncotype DX, in a UK population of intermediate risk.
Methods
OPTIMA prelim, the feasibility phase, aims to recruit 300 patients to evaluate performance and health-economics of a number of multi-parameter tests to identify test(s) to be used in the main trial and to establish the acceptability to patients and clinicians of randomisation. Patients are randomised to the standard arm or to the "test-directed treatment" arm according to the result of Oncotype DX test. The decision to roll forward into the main trial will be determined by the willingness of patients to be randomised, concordance and cost of the multi-parameter tests. Cost-effectiveness models will be based on the model developed in preparation for the OPTIMA trial, updated with contemporary evidence from the feasibility study and appropriate external data, e.g. the Ontario OncotypeDX field evaluation (prospective cohort study).
Results
OPTIMA prelim opened in Sept 2012 and has 56 patients registered (46 randomised). TSC and DMEC agreed decision rules and encouraged external collaboration to provide additional confidence and power for any decisions.
Conclusions
The success of OPTIMA relies on the integration of a multi-disciplinary team of methodologists, clinical experts and patients at all stages of the trial. The complexities of using adaptive design methodology and decision making to roll forward into the main trial are challenging but provide the most efficient use of patients and costs.
Funding
This project was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme (project number 10/34/01). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS or the Department of Health.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© Dunn et al; licensee BioMed Central Ltd. 2013. This work is published under http://creativecommons.org/licenses/by/2.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
1 University of Warwick, Warwick Medical School, Coventry, UK (GRID:grid.7372.1) (ISNI:0000000088091613)
2 Leeds Institute of Health Sciences, Leeds, UK (GRID:grid.7372.1)
3 Ontario Institute for Cancer Research, Toronto, Canada (GRID:grid.419890.d) (ISNI:000000040626690X)
4 Independent Cancer Patients Voice, London, UK (GRID:grid.419890.d)
5 University of Bristol, Bristol, UK (GRID:grid.5337.2) (ISNI:0000000419367603)
6 Mount Vernon Cancer Centre, Middlesex, UK (GRID:grid.416188.2) (ISNI:0000000404001238)
7 Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (GRID:grid.24029.3d) (ISNI:0000000403838386)
8 University College London Hospitals NHS Foundation Trust, London, UK (GRID:grid.52996.31) (ISNI:0000000089372257)